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Abstract
X-linked myotubular myopathy (XLMTM) is a congenital disorder caused by mutations of the myotubularin gene, MTM1.
Myotubularin belongs to a large family of conserved lipid phosphatases that include both catalytically active and inactive
myotubularin-related proteins (i.e., ‘‘MTMRs’’). Biochemically, catalytically inactive MTMRs have been shown to form
heteroligomers with active members within the myotubularin family through protein-protein interactions. However, the
pathophysiological significance of catalytically inactive MTMRs remains unknown in muscle. By in vitro as well as in vivo
studies, we have identified that catalytically inactive myotubularin-related protein 12 (MTMR12) binds to myotubularin in
skeletal muscle. Knockdown of the mtmr12 gene in zebrafish resulted in skeletal muscle defects and impaired motor
function. Analysis of mtmr12 morphant fish showed pathological changes with central nucleation, disorganized Triads,
myofiber hypotrophy and whorled membrane structures similar to those seen in X-linked myotubular myopathy.
Biochemical studies showed that deficiency of MTMR12 results in reduced levels of myotubularin protein in zebrafish and
mammalian C2C12 cells. Loss of myotubularin also resulted in reduction of MTMR12 protein in C2C12 cells, mice and
humans. Moreover, XLMTM mutations within the myotubularin interaction domain disrupted binding to MTMR12 in cell
culture. Analysis of human XLMTM patient myotubes showed that mutations that disrupt the interaction between
myotubularin and MTMR12 proteins result in reduction of both myotubularin and MTMR12. These studies strongly support
the concept that interactions between myotubularin and MTMR12 are required for the stability of their functional protein
complex in normal skeletal muscles. This work highlights an important physiological function of catalytically inactive
phosphatases in the pathophysiology of myotubular myopathy and suggests a novel therapeutic approach through
identification of drugs that could stabilize the myotubularin-MTMR12 complex and hence ameliorate this disorder.
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Introduction
X-linked myotubular myopathy (XLMTM) is a congenital
disorder caused by mutations of the MTM1 gene that encodes
myotubularin [1,2]. Affected males are born with severe gener-
alized hypotonia and weakness of skeletal muscles with respiratory
insufficiency. In majority of cases the disease is fatal within the first
months of life, but a proportion of affected males survive into their
teens or beyond yet are non ambulant and require ventilatory
support. Histopathologically, affected muscle fibers exhibit hypot-
rophy with a large number of centrally placed nuclei in a high
proportion of myofibers. Thus, XLMTM is considered a subtype
of centronuclear myopathy (CNM) [3]. MTM1 encodes a 39-
phosphoinositide (PtdIns3P) lipid phosphatase that catalyzes the
dephosphorylation of phosphatidylinositol-3-phosphate (PtdIns3P)
and phosphatidylinositol-3,5-bisphosphate PtdIns(3,5P)2 [4,5,6,7].
Phosphoinositides (PIs) are critical for a variety of physiological
processes, including cell proliferation, cell death, motility, cyto-
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skeletal regulation, intracellular vesicle trafficking, autophagy and
cell metabolism [8]. PtdIns3P and PtdIns(3,5)P2 are both
important regulators of membrane trafficking [9]. Similar to
humans, loss of myotubularin function in animal models also
results in clinico-pathological symptoms similar to myotubular
myopathy signifying evolutionary conservation of mechanisms
involving myotubularin [10,11,12,13].
Myotubularin is the prototypic member of one of the largest and
most conserved protein lipid phosphatase subfamilies in eukary-
otes, the myotubularin-related proteins (MTMRs) [14,15]. There
are nine catalytically active members of the MTMR family, and
six members whose catalytic sites have been inactivated through
missense changes (designated myotubularin and MTMR1-14).
While several active members are known to play crucial roles in
physiology and human diseases presumably related to loss of their
enzymatic activities, the cellular functions of catalytically inactive
members are still poorly understood. Catalytically inactive
MTMR family members are highly conserved and retained in
vertebrate genome from teleosts to humans during evolution [16]
suggesting that these inactive members have important roles in
development and diseases independent of their enzymatic
activities, as functionally redundant family members are often lost
during evolution [17]. This is further evident by a recent study that
showed that catalytically inactive form of myotubularin could
ameliorate many of the structural abnormalities seen in Mtm1
knockout mice [18].
Myotubularins form homo- and heteroligomers with themselves
and other members of the MTMR family, and the catalytically
inactive MTMRs are thought to largely form oligomers with active
family members [14,19]. These interactions appear to regulate the
sub-cellular localization or catalytic activity of the active members
of the myotubularin family. In vitro, catalytically inactive MTMR5
and MTMR9 modulate the enzymatic activity of their interacting
catalytically active partners, MTMR2, and MTMR6 and
MTMR8, respectively [20,21,22]. Functional evidence for in vivo
significance of these interactions comes from genetic studies in
humans that show that mutations of either the catalytically active
MTMR2 or its catalytically inactive binding partner MTMR13
result in similar forms of Charcot-Marie-Tooth disease
[23,24,25,26]. Similarly, mutations in either of the binding
partners MTMR2 (catalytically active) or MTMR5 (catalytically
inactive) lead to defective spermatogenesis in mice, suggesting the
biological importance of these interactions [27,28].
Myotubularin-related protein 12 (MTMR12), previously some-
times referred to as 3-phosphatase adaptor protein (3-PAP), is a
catalytically inactive member of myotubularin family that interacts
with MTM1 and MTMR2 to regulate their sub-cellular localiza-
tion in in vitro studies of non-muscle cells [29,30]. The in vivo
significance of such interactions remains unknown, especially with
reference to disease process in myotubular myopathy that
primarily affects the skeletal muscles due to lack of myotubularin
function [10]. Protein-protein interactions are critical components
of almost every biological process and any disruption of these
networks leads to pathological conditions resulting in related
diseases [31,32]. Therefore, a proper understanding of myotubular
myopathy necessitates a comprehensive knowledge of the molec-
ular mechanisms that govern such processes. We have employed
zebrafish (Danio rerio) as a vertebrate animal model to understand
the role of MTMR12 as a molecular regulator of myotubularin.
Zebrafish are an excellent vertebrate model to study skeletal
muscle development and disease due to high genomic synteny and
similar clinico-pathological changes as seen in the human
myopathies. Our studies revealed that deficiency of MTMR12
in zebrafish results in myopathy and impaired motor function
similar to that caused by loss of myotubularin. Our data suggest
MTMR12 affects muscle function primarily by regulating the
stability of myotubularin in vivo. Studies in cells, mice and humans
further implicate MTMR12 as an important player in the
pathophysiology of XLMTM.
Results
MTMR12 interacts with myotubularin in vitro and in vivo
in skeletal muscles
MTMR12 has been shown to interact with myotubularin and
form oligomers in K562 and Cos7 cells [30]. To investigate if the
binding between these proteins is a direct consequence of protein-
protein interactions or is an indirect interaction mediated through
another binding partner, GST-pull down assay was performed in
vitro (Figure 1A). Human myotubularin full-length protein was
expressed as a GST fusion protein in E. coli (MTM1-GST).
Equivalent amounts MTM1-GST or control GST protein bound
to glutathione beads were incubated with in vitro synthesized
MTMR12 protein with a B10 tag (MTMR12-B10). MTM1-GST
protein pulled down MTMR12-B10 protein whereas no interac-
tion was observed with the GST alone, suggesting myotubularin
and MTMR12 interact with each other by direct protein-protein
interactions (Figure 1A). The interaction between myotubularin
and MTMR12 was also examined in the Cos1 cell line. MTM1
and MTMR12-B10 were over-expressed in Cos1 cells and cell
extracts were immunoprecipitated by an antibody against
myotubularin (monoclonal, 1G1). This resulted in co-immuno-
precipitation of MTMR12-B10 with myotubularin but not with
control IgG or empty beads confirming that MTMR12 also
interacts with myotubularin in the cellular context as reported
earlier (Figure 1B) [30].
Mutations in MTM1 result in XLMTM, which is a congenital
myopathy that primarily affects the skeletal muscles in human
patients and animal models. Therefore, the interaction between
myotubularin and MTMR12 was investigated in skeletal muscles.
Co-immunoprecipitation was performed using protein extracts
from murine skeletal muscle (tibialis anterior) using an anti-
myotubularin monoclonal antibody (1G1) (Figure 1C). Antibody
Author Summary
Congenital myopathies are a group of heredity diseases
characterized by muscle weakness and impaired locomo-
tion that manifest in both children and adults. X-linked
myotubular myopathy (XLMTM) is a subtype of congenital
myopathy that predominantly affects males and is caused
by mutations in the myotubularin (MTM1) gene. To date,
more than 200 pathogenic mutations have been identified
in MTM1. However, no effective therapy is available to treat
patients presenting with XLMTM. This is largely due to a
lack of understanding of molecular processes perturbed in
the XLMTM disease state, thereby limiting the availability
of suitable therapeutic targets. In this study, we show that
catalytically inactive MTMR12 interacts with myotubularin
in skeletal muscle. This complex formation is required to
provide stability to myotubularin in the normal function-
ing of skeletal muscle and these interactions appear to be
disrupted in XLMTM. This work therefore offers a novel
direction for therapy development, both in XLMTM and
other genetic diseases, by identifying crucial protein
interactors of disease-causing proteins whose complexes
might be stabilized in the disease state to restore normal
function.
MTMR12-MTM1 Interactions in Skeletal Muscle
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against myotubularin co-immunoprecipitated endogenous
MTMR12 protein showing that myotubularin and MTMR12
interact in skeletal muscles. Control IgG or empty beads failed to
immunoprecipitate MTMR12 suggesting the specificity of inter-
actions between myotubularin and MTMR12. In vivo interaction
between these proteins was also investigated by immuno-
colocalization of myotubularin and MTMR12 proteins in murine
skeletal muscles. Immunofluorescence showed a striated expres-
sion of endogenous MTMR12 in mouse tibialis anterior skeletal
muscle similar to the pattern of myotubularin staining, and double
immunolabeling revealed that these colocalize at the resolution of
confocal microscopy (Figure 1D). In addition, partial co-localiza-
tion of MTMR12 was observed with ryanodine receptors, a
sarcoplasmic reticulum marker. The expression of MTMR12 was
restricted to triads as no co-localization was observed with a-
actinin at Z-lines (Figure 1D). Therefore, a combination of GST
pull down, co-immunoprecipitation and co-localization studies
support the hypothesis that myotubularin and MTMR12 interact
with each other in skeletal muscle.
Mtmr12 knockdown results in skeletal muscle myopathy
in zebrafish
To understand the function of MTMR12 in vivo, zebrafish was
used as a vertebrate animal model. The zebrafish mtmr12 gene
encodes a protein of 736 amino acids that is 69% similar and 52%
identical with the human MTMR12 protein. The expression of
mtmr12 was analyzed by whole mount in-situ hybridization and
RT-PCR in developing zebrafish embryos. Whole mount in-situ
hybridization showed that mtmr12 transcripts were expressed
ubiquitously in developing eyes, brain, heart and skeletal muscles
at 1 day post fertilization (dpf) (Figure 2A). This ubiquitous
expression of mtmr12 was similar to the ubiquitous expression of
mtm1 transcripts at 1 dpf. Similar to the zebrafish gene, human
MTMR12 transcripts have also been found to express in all organs
[33]. RT-PCR analysis further showed similar temporal expres-
sion of mtm1 and mtmr12 during zebrafish development (Figure 2A).
RT-PCR revealed that mtmr12 and mtm1 were first detected as
maternal transcripts at the 1 cell stage. Expression of these
maternal transcripts decreased during gastrulation and zygotic
expression appeared around 8 hours post fertilization (hpf). This
zygotic expression persisted in all developmental stages tested
(until 5 dpf). In murine muscle cells, Mtmr12 transcripts were
detected during proliferation as well as differentiation stages in
C2C12 cells (Figure 2B). The expression of Mtmr12 transcripts
increased steadily during differentiation followed by a decrease in
late differentiation. Comparison to Mtm1 expression revealed a
similar expression pattern with a continuous increase with the
progression of differentiation. Similar to the mRNA expression,
MTMR12 protein expression was also highest during differenti-
ation (Figure 2B). Similar expression of mtmr12 and mtm1 during
zebrafish development and in muscle cell differentiation suggests
that they may be involved in similar physiological processes.
To investigate in vivo functions of the mtmr12 gene in zebrafish,
anti-sense morpholino technology was employed to achieve
functional gene knockdown (Figure 2C–E). Morpholinos were
designed to disrupt either the translation or splicing of mtmr12
transcripts. Knockdown using either a splice site-morpholino
targeting the exon3-intron3 junction or the translational (ATG)
morpholino resulted in similar phenotypes at relatively low
morpholino concentrations (3.5–5.0 ng), suggesting the specificity
of their action. Microinjection of 1cell embryos with splice site
morpholinos resulted in mis-splicing and exclusion of exon 3 from
the mature mRNA as detected by RT-PCR assay (Figure 2D).
Mtmr12 knockdown fish (mtmr12 morphants) are smaller in size
compared to controls and exhibited a dorsal curvature through the
back and tail, instead of the normal flat dorsum, similar to mtm1
knockdown fish (Figure 2C). Axial skeletal muscles of zebrafish
embryos were examined using a birefringence assay that involves
examination of axial skeletal muscles of live zebrafish embryos
using polarized filter microscopy. Skeletal muscles of mtmr12
morphant embryos showed a reduced birefringence in comparison
to the control morpholino injected fish suggesting a defect in
skeletal muscle organization. Several mtmr12 morphants also
displayed pericardial edema. Similar phenotypes were obtained
with both translational as well as spice-site morpholinos suggesting
the specificity of morpholino knockdown. None of the commer-
cially available antibodies showed reactivity to zebrafish
MTMR12 protein, therefore, the rest of the studies were
performed with the splice-site blocking morpholino against
exon3-intron3 junction as mRNA knockdown could be assayed.
To further validate the specificity of these phenotypes and to rule
out any off-site targeting effect of morpholinos, mRNA rescues
were performed. Human MTMR12 mRNA was co-injected with
mtmr12 morpholino in zebrafish embryos. Over-expression of
MTMR12 mRNA in mtmr12 morphant fish resulted in a rescue of
phenotypes seen in mtmr12 morphant fish indicating the specificity
of morpholino targeting (Figure 2E).
To understand if the interacting partners myotubularin and
MTMR12 are involved in similar biological processes or have
functions that are independent of each other, double knockdowns
were performed. Double knockdown fish were smaller in size then
either mtm1 or mtmr12 morphant fish. Polarized live microscopy of
morphant fish also showed that birefringence of mtmr12-mtm1
double morphant zebrafish muscle was lower than in either mtm1
or mtmr12 morphant fish suggesting a severe muscle phenotype.
The exacerbated phenotypes of double knockdown fish suggests
that in addition to regulating similar biological processes these
genes may be involved in different processes independent of each
other.
MTMR12 deficiency results in impaired motor function in
zebrafish
To understand the consequences of MTMR12 deficiency on
motor function, behavioral analysis of zebrafish embryos was
performed. During early development, zebrafish embryos hatch
out of their chorions by regular contractions of their skeletal
muscles. Typically, approximately 8667.4% of control embryos
hatch by 60 hpf. In contrast, only 2569.3% of mtmr12
Figure 1. Protein-protein interactions between myotubularin and MTMR12 proteins. (A) GST pull down of MTM1-GST recombinant
protein with MTMR12 showed a direct interaction between the two proteins (above). Coomassie blue stained gel (below) showing GST and MTM1-
GST protein used in the pull down (B) Co-IP experiments from Cos-1 transfected cells with MTM1 and MTMR12-B10 constructs showing the
interaction of the two proteins in the cellular context in-vivo (C) MTMR12 co-immunoprecipitates with myotubularin (using 1G1 monoclonal
antibody) in mouse muscle lysates revealed with anti-MTMR12 polyclonal antibody (upper panel) and with the 2827 polyclonal anti-myotubularin
(bottom panel). (D) Confocal microscopic immunofluorescence studies of longitudinal frozen sections of skeletal muscle from mouse tibialis anterior
muscle with sarcomeric markers. Individual immunostaining with 2827 anti-myotubularin or anti-MTMR12 showed similar striated localization in
skeletal muscle (top panel). Double-immunostaining with both proteins showed a co-localization of myotubularin and MTMR12 to Triads and partial
co-localization with the ryanodine receptor, RyR1, a sarcoplasmic reticulum marker, but not with a-actinin, a Z-line marker. Scale bar = 10 mm.
doi:10.1371/journal.pgen.1003583.g001
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morpholino-injected embryos hatched by this time, consistent with
a continued decrease in motor activity early in development
(P,0.01, n= 100–170) (Figure 2F). Mtm1 morphant embryos
displayed similar behavior as mtmr12 morphants (19.363.39,
n = 100–150, P,0.001). Knockdown of both MTMR12 and
myotubularin resulted in a significant decrease in hatching
behavior in comparison to the mtmr12 alone morphant fish.
(9.33%64.02, P,0.001, n= 100–130).
Mtmr12 morphant fish were largely immotile and their touch
evoked response was blunted; instead of rapidly swimming out of
the field of view like control fish (6.4460.712 cm/0.1 sec), they
twitched and only moved several lengths when stimulated with a
needle (2.166(2.832 cm/0.1 sec), suggesting a significant degree
of overall muscle weakness (Movie S1, Figure 2G). This decrease
in touch-evoked response was similar to that of mtm1 morphant
fish (2.3260.855 cm/0.1 sec) (Movie S1, Figure 2G). The touch-
evoked response was also evaluated in mtm1-mtmr12 double
morphant fish. In comparison to either mtm1 or mtmr12
knockdown embryos, double morphant embryos showed a greater
degree of reduction in touch-evoked escape response
(0.9860.230 cm/0.1 sec) (Movie S1, Figure 2G). The delayed
chorion hatching and diminished touch-evoked escape behaviors
showed that mtmr12 is required for normal motor function in
zebrafish.
MTMR12 deficiency results in sarcomere disorganization
with central nucleation in skeletal muscles
To study the effect of MTMR12 deficiency on skeletal muscle
structure, ultrathin toluidine blue-stained longitudinal sections of
control and mtmr12 knockdown fish were examined at 3 dpf.
Histological examination of control muscle showed well-organized
myofibers with elongated nuclei that were localized to the
Figure 2. Expression patterns and morpholino-based knockdown of mtmr12 in developing zebrafish. (A) Whole mount in-situ
hybridization detected ubiquitous expression of mtmr12 and mtm1 transcripts in zebrafish embryos at 1 dpf (above). Below is RT-PCR analysis of
mtm1 and mtmr12 expression during zebrafish development using RNA extracts from whole zebrafish embryos at indicated developmental
timepoints. (B) Synergistic expression level of Mtm1 and Mtmr12 transcripts and protein at indicated time points of C2C12 differentiation (0–9 days)
monitored by RT-quantitative PCR (corresponding histogram, *P#0.05) and by western blot analysis (right panel). (C) Live embryos at 3 dpf injected
with control, mtmr12, mtm1 or both mtmr12 and mtm1 morpholinos in normal (left) and polarized lights (right). mtmr12 morphant fish showed a
dorsal curvature in skeletal muscle and reduced birefringence in polarized light similar to mtm1 morphant embryos. mtmr12 morphant fish also
exhibited pericardial edema (arrow). mtmr12-mtm1 double knockdown fish exhibited smaller size and reduced birefringence relative to mtm1 or
mtmr12 alone morphant fish. (D) mtmr12 mRNA levels in mtmr12 morphant zebrafish following injection of two different amounts of morpholino
(indicated below, upper panel). In mtm1 morphant fish, no residual myotubularin was observed showing that mtm1 morpholinos are completely
penetrant to the limits of detection for western blotting. (E) Over-expression of humanMTMR12mRNA rescued small body length and skeletal muscle
abnormalities observed inmtmr12morphant embryos. (F) Quantification of the chorion hatching at 60 hpf. The number of embryos was quantified in
three independent clutches (number of embryos in each clutch = 90–120). (G) Quantification of touch evoke response at 3 dpf (n = 5–8 embryos were
assayed in each morpholino group).*P#0.01.
doi:10.1371/journal.pgen.1003583.g002
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periphery of muscle fibers (Figure 3A). In mtmr12 knockdown fish,
areas lacking sarcomeric organization were observed (Figure 3A,
arrowhead). Moreover, occasional rounded, central nuclei were
seen in skeletal muscles of the morphant fish but were absent in the
control fish (Figure 3A, arrow). Remarkably, the sarcomeric
disorganization with central nucleation was very similar to the
histological changes observed in mtm1 knockdown fish (Figure 3A,
arrow). The proportion of fibers with central nuclei was almost
similar in mtmr12 morphant (54.567.1%) and mtm1 morphant
(57.867.1%) fish and significantly higher than normal controls
(2.261.1%).Mtm1-mtmr12 double knockdown fish exhibited severe
muscle abnormalities with larger number of myofibers displaying
sarcomeric disorganization and central nucleation (69.266.4%)
than single morphants (Figure 3A). To evaluate if the sarcomeric
defects observed in mtmr12 morphant fish are developmental or
due to degenerative changes in muscle, skeletal muscle histology
was evaluated at different time points during zebrafish develop-
ment. A comparison of Hematoxylin and Eosin stained skeletal
muscle sections at 2 dpf and 3 dpf showed an increase in
sarcomeric disorganization at 3 dpf in mtmr12 morphant fish
(Figure 3C). This suggests the sarcomeric defects seen in mtmr12
morphant fish are due to degenerative processes in disease state.
The number of central nuclei per myofiber showed no significant
change during development in mtmr12 morphants (Figure 3D). A
comprehensive histological analysis of Hematoxylin and Eosin
stained sections of wild-type and mtmr12 morphant showed no
other histological abnormalities in other organs.
To identify ultrastructural defects in sub-cellular compartments
of skeletal muscle, transmission electron microscopy was per-
formed at 3 dpf (Figure 4). Longitudinal views of the skeletal
muscle in mtmr12 morphant fish revealed significant myofibrillar
disarray in comparison to highly organized myofibrillar structures
with peripheral elongated nuclei in control fish (Figure 4A, C).
Notably, skeletal muscle of mtmr12 morphants showed an increase
in absent or disorganized Triads in the myofibers in comparison to
the control fish (Figure 4A, C). In addition, similar to the whorled
membrane structures reported in myotubularin deficiency [13],
mtmr12 fish also exhibited whorled membrane structures in skeletal
muscle (Figure 4E). Mtm1 morphant fish displayed sarcomeric
disorganization, with central nucleation and triad disorganization
Figure 3. Abnormal histology of MTMR12-deficient zebrafish. (A)Toluidine blue stained longitudinal sections of skeletal muscle in control
and morphant fish at 3 dpf. In comparison to the control fish, mtmr12 morphants showed disorganized myofibers (arrowhead) with central
nucleation (arrow), similar to histological changes observed in the skeletal muscle of mtm1 morphant fish (arrow). Knockdown of both mtm1 as well
as mtmr12 results in severe muscle disorganization greater than seen in mtm1 or mtmr12 alone morphants. (B) Centrally nucleated myofibers were
quantified. Serial sections from 3–4 different embryos were analyzed and the relative number of centrally nucleated fibers in the middle somites (10–
13) were counted. (C) Hematoxylin and Eosin staining of mtmr12 morphant zebrafish at different time points. An increase in sarcomeric
disorganization was observed at 3 dpf in comparison to 2 dpf in mtmr12 morphants (arrow) (D) Centrally nucleated myofibers were quantified. Serial
sections from 6 different embryos were analyzed and the relative number of centrally nucleated fibers in the middle somites (10–13) were counted.
Scale bar = 10 mm.
doi:10.1371/journal.pgen.1003583.g003
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as previously reported for myotubularin deficiency in zebrafish,
mouse and humans (Figure 4B). The ultrastructural defects in
double knockdown fish were more severe than either mtm1 or
mtmr12 knockdown fish (Figure 4D). Myofibers lacked the
sarcomeric organization with absence of Z-lines in many
myofibers. The numbers of disorganized triads also showed a
small but significant increase in double knockdown fish
(68.8610.08%) compared to mtm1 (63.568.00%) or mtmr12
(57612.12%) fish (p,0.005, n = 5 embryos, 15 myofibers in each
embryo) (Figure 4G). Like in myotubularin and MTMR12
deficient muscles, whorled membrane structures were also
observed in mtmr12-mtm1 double knockdown zebrafish (4F). These
abnormal membrane structures are seen in several types of
myopathies, however, their functional role in disease pathology is
not known. In a previous study on double mtm1-mtmr14
knockdown, the severe phenotype was a result of an increase in
autophagy in the absence of both proteins [34]. Ultrastructural
examination of mtm1-mtmr12 double knockdown exhibited no
increase in autophagic vacuoles suggesting different pathological
mechanism in two different disease states.
Loss of MTMR12 results in reduced stability of
myotubularin protein in zebrafish
Catalytically inactive myotubularin family members have been
shown to regulate the activity and/or sub-cellular localization of
their catalytically active interacting partners. Previous co-trans-
fection experiments in cell culture have suggested that MTMR12
is required to regulate the subcellular localization of myotubularin
[30]. Therefore, to investigate if MTMR12 controls the subcellular
localization of myotubularin in zebrafish skeletal muscle, immu-
nofluorescence studies were performed. Immunostaining of
skeletal muscle of control fish with antibody against myotubularin
detected a striated expression pattern of myotubularin protein
corresponding to the triad compartment (Figure 5). Strikingly,
highly reduced levels of myotubularin labeling were seen in
morphant muscle as compared to control skeletal muscle.
However, the residual myotubularin protein showed similar
localization as the control fish. These data suggest that loss of
MTMR12 does not affect subcellular localization of myotubularin
in skeletal muscle in vivo.
These observations suggest that MTMR12 is likely involved in
regulating the stability of myotubularin. To address this point, we
quantified myotubularin protein levels in mtmr12 morphant fish.
Western blot analysis, performed in three independent groups of
embryos injected with mtmr12 morpholino, revealed a ,90%
reduction in myotubularin levels in mtmr12 morphant fish in
comparison to the controls (Figure 6A). This suggests that
myotubularin-MTMR12 interactions result in stabilization of
myotubularin in zebrafish skeletal muscle. To investigate whether
MTMR12 regulates myotubularin levels in a mammalian system,
Mtmr12 siRNA C2C12 cell lines were created. SiRNA-mediated
knockdown of Mtmr12 in C2C12 myoblasts or differentiated
myotubes resulted in decreased levels of myotubularin protein
compared to scrambled control siRNAs (Figure 6B and 6C).
MTMR12 deficient C2C12 myotubes also mimicked cellular
changes previously seen in Mtm1 knockdown C2C12 cells [35].
Mtmr12 knockdown in C2C12 cells resulted in an increase in levels
of the intermediate filament protein desmin which were associated
with abnormal filament shape (arrow) in both myoblasts and
myotubes (Figure 6C and 6D). However, no change in differen-
Figure 4. Ultrastructural abnormalities inMTMR12 deficiency. Transmission electron micrographs of skeletal muscles in control and morphant
fish. In comparison to wild-type controls (A), mtmr12 morphant fish displayed abnormal triads (C, high magnification, inset). mtm1 morphant muscle
also had absent or disorganized triads (B). mtmr12-mtm1 double knockdown morphants displayed exacerbated defects in muscle with many absent
Z-lines in addition to disorganized triads (D inset shows high magnification view). Higher magnification examination showed whorled membranous
structures in mtmr12 and mtmr12-mtm1 morphants (E–F). (G) Histograms represent quantification of disorganized triads of the single or double
morphants. Total number of triads were counted in at least 15 myofibers within each embryo (n = 5 embryos). *P#0.05, ns: statistically not significant.
doi:10.1371/journal.pgen.1003583.g004
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tiation markers such as myogenin or myotube formation was
observed in Mtmr12 knockdown cells (Figure 6C and 6E)
suggesting that Mtmr12 deficiency does not affect the differenti-
ation program in C2C12 cells.
To determine whether MTMR12 protein stability is regulated
by myotubularin, MTMR12 levels were assessed in Mtm1
knockout mice and Mtm1 knockdown C2C12 cells (Figure 6F–
G). In Mtm1 knockout mice, expression of MTMR12 was reduced
in skeletal muscle in pre-symptomatic (2 weeks) as well as in
symptomatic phases of disease progression (5 weeks) (Figure 6F).
Similarly, in Mtm1 knockdown cell lines, a significant decrease in
MTMR12 expression levels was also observed (Figure 6G).
Combined, these data support the notion that the MTMR12-
myotubularin interaction enhances stability of the complex in
muscle cells in vitro and in skeletal muscle in vivo.
The only known and well-characterized biochemical functions
of myotubularin related proteins is the dephosphrylation of
phospholipids. Previous data have shown that Mtm1 mice and
mtm1 zebrafish morphants display an increase in PtdIns3P levels
(the substrate of myotubularin) [11,13] To investigate if mtmr12
knockdown also affects PItdIns3P levels in skeletal muscle as seen
in myotubular myopathy, PtdIns3P staining was performed on
control and mtmr12 morphant skeletal muscle. Indirect immuno-
fluorescence on MTMR12-deficient muscle showed an increase in
PtdIns3P staining compared to control suggesting that the
reduction of myotubularin levels is paralleled by an overall
decrease in its enzymatic activity (Figure 5). To quantify the levels
of PtdIns3P in the absence of either myotubularin or MTMR12 or
both, a lipid-protein overlay PtdIns3P ELISA was performed on
lipid extracts from 3 dpf zebrafish morphant fish. As shown
Figure 5. Myotubularin and PtdIns3P alterations in mtmr12 morphants. (A) Immunofluorescence of control and mtmr12 knockdown fish
showed significantly decreased myotubularin staining in mtmr12 knockdown fish in images taken under identical conditions. Immunofluorescence
detection of PtdIns3P showed apparent increases of this myotubularin substrate in mtmr12 morphant embryos as compared to controls. (B) PtdIns3P
levels are increased in mtmr12, mtm1 and mtm1-mtmr12 morphant zebrafish, *P#0.05. Total lipids were extracted from zebrafish at 3 dpf and
PtdIns3P levels were measured using a lipid-protein overlay enzyme-linked immunosorbent assay.
doi:10.1371/journal.pgen.1003583.g005
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previously [11,13], absence of myotubularin resulted in an
increase in PtdIns3P levels in mtm1 morphant embryos
(Figure 5B). In the absence of MTMR12 or both myotubularin
and MTMR12, a significant increase in PtdIns3P levels were seen
over levels in both control and myotubularin morphant fish. This
suggests that in addition to regulating myotubularin activity,
Figure 6. Loss of protein stability in the absence of myotubularin-MTMR12 interactions. (A) Knockdown of mtmr12 resulted in a strong
decrease of myotubularin protein in mtmr12 morphant zebrafish at 3 dpf by western blotting. Western blot analysis was done on three
independently injected clutches (n in each clutch= 50–75). The histogram at right shows normalized amounts of myotubularin in control and mtmr12
morphant zerbrafish, *P#0.01. (B) siRNA-mediated knockdown of Mtmr12 in C2C12 myoblasts leads to decreased protein levels of MTM1. Histograms
showed western blot quantification of MTM1 and MTMR12 with reference to a-actinin as a loading control. Data represent mean of 3 independent
experiments, * P,0.05. (C) Mtmr12 siRNA treated myoblasts were differentiated into myotubes and tested for protein expression of MTM1, MTMR12,
desmin and myogenin. Mtmr12 knockdown in myotubes leads to decreased protein levels of MTM1 and increased amounts of the intermediate
filament protein desmin, but do not affect myogenin levels. a-Actinin was used as the loading control (histograms). Data represent mean of 3
independent experiments, * P,0.05. (D) Labeling of a-actinin and desmin in C2C12 myoblast and myotubes treated with Mtmr12 siRNA or scramble
control siRNA. Mtmr12 knockdown cells showed abnormal accumulation of desmin in both stages (arrow). (E) Quantification of myotubes at 2, 4, 6
and 9 days of differentiation showed no significant differences between siRNA-Mtmr12 cells and scramble siRNA. Data were obtained from 2
independent experiments (* P,0.05) and minimum of 100 cells per condition were counted. (F) Mtm1 knockout mice exhibited highly reduced levels
of MTMR12 protein in skeletal muscle at pre-symptomatic (2 weeks) as well as symptomatic stages (5 weeks). The histogram on right shows
normalized amounts of MTMR12 in control and Mtm1KO Mice, *P#0.05. (G) siRNA-based Mtm1 knockdown in C2C12 cells led to no reduction in
MTMR12 protein as seen by western blot analysis. b-actin/GAPDH were used as loading controls in western blots. The histogram at right shows
normalized amounts of MTMR12 in control and Mtm1 knockdown cell line, *P#0.05.
doi:10.1371/journal.pgen.1003583.g006
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MTMR12 may also be regulating the functions of other PtdIns3P
phosphatases.
Over-expression of MTM1 improves skeletal muscle
function in Mtmr12 morphants
Mtmr12 morphant fish displayed reduced levels of myotubularin
protein and similar pathological changes to those seen in
myotubularin deficiency, suggesting that the ability of MTMR12
to stabilize endogenous myotubularin levels in vivo may be a
primary physiological role. These findings gave rise to the
intriguing possibility that overexpression of myotubularin may be
able to reverse the phenotypes associated with MTMR12
deficiency in zebrafish. To test this hypothesis, we overexpressed
exogenous human MTM1 mRNA to investigate its ability to
rescue the muscle phenotype in mtmr12 morphant fish and
evaluated the resulting skeletal muscle phenotypes by birefrin-
gence assay and electron microscopy (Figure 7). Overexpression of
MTM1 mRNA in mtmr12 morphant fish restored the birefringence
to almost normal levels (Figure 7A). While the skeletal muscle
birefringence was drastically improved, the length of zebrafish
embryos was smaller (7565.4% of control fish) suggesting
MTMR12 may have additional functions independent of
myotubularin. The ultra-structure of skeletal muscle was also
significantly improved with a decrease in fraction of abnormal
triads. This result strengthens the finding that an important role of
MTMR12 is to provide stability to myotubularin protein and
hence regulate its function. The mtm1-mtmr12 double knockdown
fish exhibited severe muscle defects consistent with the idea that
MTMR12 may have independent functional roles in addition to
providing stability to myotubularin. This was investigated by
overexpressing MTM1 RNA in mtm1-mtmr12 double knockdown
fish. Overexpression of MTM1 resulted in a moderate improve-
ment in birefringence as well as skeletal muscle pathology in
double knockdowns as quantified by number of normal triads in
skeletal muscle of rescued fish. Nevertheless, rescued fish were still
smaller in size (0.6460.029) than wild-type controls (1.0060),
consistent with the notion that MTMR12 may have functions
independent of MTM1 in vivo (Figure 7 C and E).
To test the ability of MTMR12 to rescue the phenotypes
associated with myotubularin deficiency in skeletal muscle, human
MTMR12 RNA was overexpressed in mtm1 morphant fish. This
resulted in partial rescue of the muscle phenotype in these fish as
seen by an increase in birefringence and body length (7164.9% of
normal controls) of mtm1 morphant fish rescued with MTMR12
mRNA versus mtm1 morphant (6463.68% of normal controls),
however, without any significant reduction in disorganized triads
(Figure 7B, C and E). These observations suggest that it is the
missing catalytic activity or other gene-specific function of
myotubularin that is primarily responsible for the pathology of
XLMTM.
Myotubularin-MTMR12 interactions are perturbed in
XLMTM
The significance of MTM1-MTMR12 interactions was inves-
tigated in the human neuromuscular disease XLMTM. In
XLMTM, more than 200 mutations have been reported that
are distributed on different domains of the myotubularin protein
(http://www.dmd.nl/). In addition to nonsense mutations, a large
number of missense mutations in various myotubularin domains
have been shown to be pathogenic. To test, if disease causing
mutations in myotubularin affect its interaction with MTMR12,
interactions between mutant myotubularins and wild-type
MTMR12 were examined. A series of human myotubularin
proteins modeling human missense mutations in different domains
were constructed (Figure 8A). Exogenous wild type or mutant
myotubularins were co-expressed with MTMR12-GFP protein in
Cos7 cells. Immunoprecipitation of protein extracts with a
myotubularin specific antibody revealed that missense mutations
in the GRAM or RID domains abolished the interaction of
myotubularin with MTMR12 (Figure 8B). As over-expression in
cell culture may not represent the physiological milieu, myotubes
from XLMTM patients were also used to test if the pathogenic
mutations on myotubularin protein affect myotubularin-
MTMR12 interactions. Examination of XLMTM patient myo-
tubes showed all mutations tested resulted in highly reduced levels
of myotubularin compared to control samples. In addition,
MTMR12 levels were also reduced in these patients suggesting
an overall perturbation of myotubularin-MTMR12 complexes in
XLMTM (Figure 8C).
Discussion
Studies presented in this work were aimed at gaining insights
into the molecular regulatory mechanism(s) of myotubularin
function in vivo. Previous studies have shown that MTMR12 is
an interacting partner of myotubularin in vitro [30,33]. Here, we
show that absence of catalytically inactive phosphatase MTMR12
protein resulted in skeletal muscle myopathy and pathological
changes similar to XLMTM due to abrogation of protein-protein
interactions between myotubularin and MTMR12 resulting in
reduced stability and loss of myotubularin protein function.
The interaction between myotubularin and MTMR12 in
skeletal muscle and co-localization at the triad certainly suggests
that they might be functioning together in similar biological
processes in muscle cells. This hypothesis is supported by
knockdown studies on the mtmr12 gene in zebrafish that resulted
in myopathic muscle in the affected fish similar to the
myotubularin deficient zebrafish model [13]. To understand if
these proteins function in similar biological processes or play roles
in other processes independent of each other, mtm1-mtmr12 double
knockdown zebrafish were created. The phenotype of double
knockdown zebrafish was more severe than fish deficient in either
myotubularin or MTMR12 alone. Further, inability of MTM1 to
rescue all the defects observed in double knock-down fish suggests
that these proteins may play additional functions that are
independent of each other either by interacting with other proteins
within or outside of the myotubularin family. Previous studies have
shown that in addition to myotubularin, MTMR12 also interacts
with another catalytically active member, MTMR2, by co-
immunoprecipitation and yeast two hybrid interactions [29,30].
Therefore, future studies on identification of protein complexes of
myotubularin and MTMR12 proteins may help in identifying
other pathways that are regulated by these proteins.
The presence of similar pathological changes in mtmr12
knockdown and XLMTM muscles, such as myofibrillar disarray,
excessive central nucleation, triad disorganization and presence of
whorled membranous structures, suggests that mtmr12 is a crucial
regulator of disease pathology in XLMTM. Moreover, these
pathological changes in zebrafish manifest early in zebrafish
development (2–3 dpf), similar to pathological changes seen in
human patients. As loss of mtmr12 resulted in clinical symptoms
similar to those associated with centronuclear myopathies,
MTMR12 represents an excellent candidate gene for patients
with centronuclear myopathy but unknown genetic diagnosis.
However, sequencing of 108 such cases failed to identify any
pathogenic mutations in MTMR12, suggesting MTMR12 may
account for a small subset of patients or is mutated in a clinically
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different disease, perhaps with a skeletal muscle component, but
related also to other functions of MTMR12 (V.A. Gupta,
unpublished data). In our cellular models of MTMR12 deficiency,
highly reduced levels of MTM1 were observed. Therefore, any
genetically unknown cases exhibiting low levels of myotubularin
without any MTM1 mutations may also be good candidates for
testing for MTMR12 mutations. Next generation sequencing
technologies have been exhibited great promise in identifying rare
gene variants and may yet identify MTMR12 mutations in the
future. Regardless, these studies show a crucial role for MTMR12
function in XLMTM disease pathology.
Complex formation between some catalytically inactive and
active partners in the myotubularin family has been shown to
increase the activity of the catalytically active binding partner
either by recruitment to specific membrane subdomains rich in
lipid substrate or by increasing the allosteric activity. In the
absence of MTMR12 an increase in PtdIns3P was observed
suggesting a decrease in myotubularin and/or another partner’s
enzymatic activity. However, unlike other catalytically active-
inactive pairs, MTMR12 primarily regulates the function of
myotubularin protein by affecting protein levels instead of
modulating the enzymatic activity [22,36]. Interestingly, PtdIns3P
Figure 7. Rescue of mtmr12morphant phenotypes by MTM1. The ability of human MTM1 or MTMR12 transcripts to rescue abnormalities seen
in morphant zebrafish was classified in to phenotypic index of five groups: Normal, mild, moderate, severe and dead, described in the table
depending on body length, birefringence and ultrastructure of skeletal muscle. (A) Polarized light microscopy of 3 dpf live embryos showed that
birefringence of mtmr12 morphant embryos increased significantly upon overexpression of human MTM1 mRNA. (B) Overexpression of human
MTMR12 mRNA in mtm1 morphant fish resulted in a mild rescue of skeletal muscle defects as seen by birefringence of zebrafish embryos. (C)
Overexpression of human MTM1 mRNA in mtm1-mtmr12 morphant fish resulted in a moderate rescue of skeletal muscle defects as seen by
birefringence of zebrafish embryos. (D) Electron microscopy showed normal skeletal muscle structure of mtmr12 and mtm1-mtmr12 morphant fish
rescued with MTM1 mRNA but displayed disorganized triads in mtm1 morphants that were rescued with MTMR12 mRNA. (E) Quantification of the
body length and disorganized triads in morphant and rescued fish. Body length was measured in 10–15 embryos in each group. Total number of
triads were counted in at least 15 myofibers within each embryo (n = 5 embryos). P#0.05.
doi:10.1371/journal.pgen.1003583.g007
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levels were higher in mtmr12 morphant fish in comparison to mtm1
morphant fish, suggesting that MTMR12 may function in
regulating the enzymatic activity/protein stability of other
phospholipid phosphatases in cells. In the absence of MTMR12,
highly reduced levels of myotubularin protein was observed
suggesting that protein-protein interactions between these proteins
are required for maintaining myotubularin stability. Similarly,
decreased levels of MTMR12 were seen in myotubularin deficient
cells and mice suggesting that stability of MTMR12 is also
dependent on the interaction with myotubularin.
The abnormalities observed in MTMR12 deficient fish appear
mainly due to loss of function of myotubularin as overexpression of
Figure 8. Myotubularin-MTMR12 interactions in XLMTM. (A) Schematic diagram of different domains of myotubularin protein displaying
representative pathogenic mutations found in XLMTM patients or an artificial inactivating mutation C375S* (GRAM, N terminal lipid or protein
interacting domain; RID, putative membrane targeting motif; PTP/DSP, phosphatase domain; SID, protein-protein interacting domain; CC, coiled-coil
domain; PDZB, PDZ binding site). (B) Wild-type or mutant MTM1-B10 fusion proteins with indicated missense mutations and wild-type MTMR12-GFP
proteins were overexpressed in Cos1 cells. Immunoprecipitation of protein extracts with anti-B10 tag antibody showed that mutations on GRAM or
RID domains disrupt the interactions between MTM1 and MTMR12. (C) Western blotting of XLMTM patient myotubes showed that mutants that
decrease the stability of myotubularin protein also results in a reduction of MTMR12 levels. Histograms depict the western quantification for panels
(B) and (C). Asterisks indicate statistically significant differences from measurements of wild type controls, P#0.05.
doi:10.1371/journal.pgen.1003583.g008
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MTM1 mRNA dramatically improved the skeletal muscle defects
observed in mtmr12 morphant embryos while overexpression of
catalytically inactive MTMR12 mildly improved muscle pathology
in mtm1 morphant embryos. This suggests that enzymatic activity
of myotubularin is required for its protein function, which was also
seen, in a previous study where myotubularin deficiency could be
rescued by catalytically active MTMR1 and MTMR2 [13].
Recent work also suggests that several but not all structural
abnormalities observed in myotubularin deficiency can be rescued
by over-expression of a catalytically inactive form of myotubularin
[18]. As the catalytically inactive MTMR12 only partially but
significantly rescues myotubularin function, it supports these
recent findings [18] and suggests that MTMR proteins partially
compensate for the lack of MTM1 through functions independent
of their catalytic activity.
This implies that the inability of catalytically inactive MTMR12
to rescue myotubularin function is not only due to the lack of
phosphatase activity but could also be due to other properties of
myotubularin not compensated by all MTMRs. MTMR12 also
interacts with another catalytically active member, MTMR2, by co-
immunoprecipitation and yeast two hybrid [29,30]. Further
MTMR2 and MTMR13 also interact by direct protein-protein
binding. Mutations in genes encoding MTMR2 and MTMR13
have both been associated with Charcot-Marie-Tooth (CMT)
disease raising the possibility that MTMR12 deficiency may result
in neurological defects such as those seen in CMT.Mtmr2 as well as
Mtmr13 knockout mice exhibit a progressive neuropathy that
becomes evident much later in the life span of these mice (,6
months) [27,37]. In comparison, no such neurological defects were
seen in mtmr12morphant fish, which could be due to early mortality
of these embryos (between 3–5 dpf), before such changes become
evident. Finally, it is worth noting that the ability of human MTM1
mRNA to rescue zebrafish mtm1 morphants reinforces the notion
that these orthologues have been functionally conserved despite
their considerable evolutionary distance, validating the relevance of
the zebrafish model to studies of human XLMTM.
Studying the interaction of MTMR12 with myotubularins
modeling various human mutations illuminates the role of
myotubularin-MTMR12 interactions in XLMTM. Missense mu-
tations in the N-terminal GRAM and RID domains resulted in
abolishment of interaction between myotubularin and MTMR12.
This was a surprising finding as previous studies have shown the
myotubularin family members interact with each other through
their SID or coiled-coil domains. It was also shown that an isoform
of MTMR12 lacking the SID domain showed no interaction with
myotubularin protein [30]. One reason for this discrepancy is that
many of the previous studies have been performed using deletion
constructs of different domains that may have a different effect on
protein confirmation and thus its interactions than the missense
changes we studied. Nonetheless a study of interactions between
MTMR6 and KCa3.1 proteins has shown that along with the
coiled-coil domain, the PH-GRAM domain is also required for
protein-protein interactions [38]. Similarly, oligomerization of
MTMR2-MTMR13 in a complex occurs independent of coiled-
coil domains [39]. Analysis of XLMTM patient myotubes showed
that many mutations of myotubularin that result in low levels of
myotubularin protein also lead to decreases in MTMR12 levels.
Many patients with these types of myotubularin mutations are
described with severe phenotypes and a further reduction of
MTMR12 may exacerbate the clinical severity as seen in
myotubularin-MTMR12 double knockdown zebrafish.
Apart from the type III intermediate filament desmin [35], our
study identifies a second interactor of myotubularin in skeletal
muscle and underlines the concept that protein-interactions
between myotubularin and MTMR12 are crucial for disease
pathology in XLMTM. We propose a model whereby disruption
of interactions between MTM1-MTMM12 results in destabiliza-
tion of both partners in the complex, leading to centronuclear
myopathy (Figure 9). As loss of MTMR12 results in reduction of
myotubularin, we suspect that primary mutations of MTMR12
may result in centronuclear or related myopathies. As protein
interactions play critical roles in almost all biological processes,
efforts are currently focused on identifying drugs that can stabilize
protein-protein interactions [40]. Stabilizing protein-protein
interaction between myotubularin and MTMR12 may result in
restoration of normal skeletal muscle function in XLMTM
patients with certain missense mutations of myotubularin.
Materials and Methods
Fish and embryo maintenance
Fish were bred and maintained as described previously [41].
Control embryos were obtained from the Oregon AB line and
were staged by hours (hpf) or days (dpf) post fertilization at 28.5uC.
All animal work was performed with approval from the Boston
Children’s Hospital Animal Care and Use Committee.
Ethics statement for mouse work
Animals were housed in a temperature-controlled room (19–
22uC) with a 12:12 hr light/dark cycle. Mice were humanely killed
by CO2 inhalation followed by cervical dislocation, according to
national and European legislations on animal experimentation.
Whole mount in situ hybridization
Isoform-specific riboprobes were constructed from the 39UTRs
of mtm1 and mtmr12 using adult zebrafish RNA. Total RNA was
extracted from adult zebrafish muscle tissue using Trizol
(Invitrogen, Carlsbad, CA, USA). cDNAs were synthesized using
superscript RT-PCR system (Invitrogen) and cloned in
pZEM7Z(+) using XhoI and BamHI sites respectively. Sense or
antisense digoxigenin-labeled riboprobes were synthesized by in
vitro transcription using dig-labeling kits (Roche Applied Sciences,
Indianapolis, IN, USA). Whole mount in situ hybridization was
performed as described [42]. Imaging was performed using a
Nikon SMZ1500 microscope with a Spot camera system.
Morpholino knockdown and mRNA rescue
Two splice site blocking morpholinos targeting different exon-
intron boundaries, and a translational blocking morpholino, were
designed to knockdown zebrafish mtm1 or mtmr12 transcripts
(Genetools, Philomath, OR, USA). The morpholino sequences are
mtm1 (translational): AGCCAGACCCTCGTCGAAAAGTCAT,
mtmr12 (translational): CTCCTCCGCTCCCCAAACTCAA-
CAT, mtmr12 (exon3-intron3): GCCCGGTCAACTGTCCT-
TACCATCT. Morpholino against human b-globin was used as
a negative control for all injections. Morpholinos were dissolved in
1X Danieau buffer and 1–2 nl (1–10 ng) were injected into 1cell
embryos.
For rescue experiments, full-length human MTM1 and
MTMR12 cDNAs were cloned in to a PCSDest destination vector
(a gift from Nathan Lawson) using Gateway technology (Invitro-
gen, Carlsbad, CA, USA). mRNA was synthesized in vitro using
mMessage kits (Ambion, Austin, TX, USA). 50–200 pg of mRNA
was injected into embryos at the 1 cell stage.
Immunofluorescence
Indirect immunofluorescence staining was performed on
zebrafish frozen sections as described previously [43]. Primary
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antibodies used for zebrafish experiments were rabbit anti
myotubularin HPA010008 (Sigma-Aldrich, St. Louis, MO, USA)
and anti PtdIns3P, Z-P345b (Echelon Bioscience, Salt Lake City,
UT, USA). For mouse muscle staining, tibialis anterior sections
(8 mM) were labeled successively with the anti-MTM1 polyclonal
antibody (2827) [35] and the anti-MTMR12 antibody (GTX119163,
GeneTex Inc., Irvine, CA, USA). Briefly, after permeabilization and
blocking, the anti-MTM1 antibody was applied (diluted at 1/500) on
section for 2 h at RT. After washing steps, sections were incubated
with the secondary antibody coupled to Alexa fluor 488 (Invitrogen)
for 45 min followed by a second step of washing cycles and a
blocking step. Then, the anti-MTMR12 antibody was applied on
section for 2 h at RT and revealed by the incubation with a
secondary antibody coupled to Alexa fluor 594 (Invitrogen). After
final washing, sections were fixed, mounted and observed under
confocal microscope (Leica SP2 MP confocal microscope). The
monoclonal antibody against RyR1 (1C3) was a gift from Dr Isabelle
Marty (Grenoble, France). The mouse anti a-actinin antibody (clone
EA-53) was from Sigma (Sigma-Aldrich, St. Louis, MO, USA).
Western blotting
Zebrafish embryos were homogenized in a buffer containing Tris-
Cl (20 mM, pH 7.6), NaCl (50 mM), EDTA (1 mM), NP-40 (0.1%)
and complete protease inhibitor cocktail (Roche Applied Sciences).
Western blotting was performed as described previously [43].
Primary antibodies used were mouse monoclonal anti-myotubularin
1G1 [19], rabbit polyclonal anti-myotubularin R2827 [44] and
mouse anti-b-actin clone AC-15 (Sigma-Aldrich, A5441 at 1:2000).
Mouse monoclonal antibodies for Desmin and the sarcomeric a-
actinin were purchased from Sigma-Aldrich (clone D33 and Clone
EA-53, respectively). The mouse monoclonal antibody for myogenin
was fromR&D system (Clone 671037). Protein bands were quantified
using Quantity One software (Biorad, Hercules, CA, USA).
Cell culture and siRNA
C2C12 cells were cultured in proliferation medium (Dulbecco
medium supplemented with 20% FCS and 400 U/ml of
Gentamycin) and differentiation was enhanced by decreasing the
FCS in the media to 2% for 1 day and then accelerated by
replacing the FCS by 5% Horse serum. Cells were kept in
differentiation medium for 9 days with medium replacement every
2 days. For siRNA experiments the Accel Smart Pool siRNA
(Thermo Scientific, Dharmacon) were used to knockdown
Mtmr12 in C2C12. Myoblasts (at 30–40% of confluence) were
washed with PBS and incubated with siRNA medium containing
permeable Accel siRNA pool against Mtmr12 (CCAGCAGUAUA-
GAGGAAUA, GCGCUAUUUACGUUGGAUU, CCCGUGG-
GUUUAUAUAUUG, GGAUUAAGCUAUUAGACUG) or
scrambled control siRNAs diluted to the appropriate concentration.
After 72 hours, cells were washed with PBS and incubated with
Figure 9. MTM1-MTMR12 interactions in normal and disease states. Under normal conditions, MTM1 and MTMR12 interact in skeletal
muscle and regulate skeletal muscle architecture and function. Loss of function mutations of MTM1 (red cross) in skeletal muscle are associated with
centronuclear myopathy and with a secondary reduction in MTMR12 levels. In centronuclear myopathy, disease causing missense mutations (red
circle) that disrupt interactions between MTM1 and MTMR12 result in decreased stability of myotubularin causing myotubular myopathy associated
with reduced levels of MTMR12. Loss of MTMR12 in zebrafish and mammalian cells, results in decreased levels of myotubularin resulting in
pathological changes similar to centronuclear myopathy.
doi:10.1371/journal.pgen.1003583.g009
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proliferation medium or differentiation medium and left for 9 days
in order to obtain myotubes. Myotubes (containing min 2 nuclei)
were counted blindly under the microscope (bright field) at different
stages and minimums of 100 cells per well were counted.
GST pull down and co-immunoprecipitation (co-IP)
assays
MTMR12 constructs were transferred to Gateway destination
vectors for eukaryotic expression (pSG5 from Agilent Technologies
(Santa Clara, CA, USA), with tag corresponding to the B10 epitope of
estrogen receptor or GFP) and pSG5-MTM1-B10 and pcDNA3.1-
MTM1 were used for co-immunoprecipitation assays in Cos1 cells.
For GST-pull down experiment, MTM1 cDNA was inserted into the
prokaryotic expression vector (pGex4T3, Invitrogen, Carlsbad, CA,
USA). Myotubularin recombinant proteins were produced in the
BL21-Rosetta 2 strain (Novagen, Billerica, MA, USA); GST fusion
proteins were purified and coupled to glutathione sepharose beads as
described before [35]. pSG5-MTMR12-B10 was translated in vitro
according to the manufacture protocol (TNT coupled reticulocyte
lysate System, Promega, Madison, WI, USA). Resulted translated
protein was diluted in Co-IP buffer: (50 mM Tris-Cl pH 7.5,
100 mM NaCl, 5 mM EDTA, 5 mM EGTA, 1 mM DTT, 0,5%
Triton X-100, 2 mM PMSF) supplemented with complete protease
inhibitor tablet (Roche Applied Sciences, Indianapolis, IN, USA)
and 1 mM Leupeptin and 1 mM pepstatin (Sigma, St. Louis, MO,
USA). Homogenates were centrifuged at 14.0006g and pull down
was performed as previously described [35]. GST coupled beads was
used as negative control. For Co-IP Cos7 cells were transiently
transfected with pcDNA3.1-MTM1 and pSG5-MTMR12-B10
constructs or with pSG5-MTM1-B10 and pSG5-MTMR12-GFP
for 24 hours and homogenized in ice-cold lysis buffer (10 mM Tris-
Cl, pH 7.6; 140 mMNaCl; 5 mMEDTA; 5 mM EGTA; 0.5% [v/
v] Triton X-100; and 2 mM PMSF). Homogenates were incubated
with mouse monoclonal anti-myotubularin 1G1 [19], or B10
epitope (Mab anti-B10, IGBMC, Illkirch, France) [35]. Interacting
proteins were analysed by Western blot as mentioned before.
The panel of amino acid changes was engineered by PCR-based
mutagenesis from the cDNA encoding the wild-type protein
(MTM1) using PFU DNA polymerase (Agilent technologies). All
constructs were verified by sequencing.
Co-IP experiments in muscle were performed from fresh murine
tibialis anterior muscles that were dissected and homogenized with a
dounce homogenizer in ice-cold co-IP buffer (50 mM Tris-Cl,
pH 7.5; 100 mM NaCl; 5 mM EDTA; 5 mM EGTA; 1 mM
DTT; 0.5% Triton X-100; and 2 mM PMSF) supplemented with
0.05% (w/v) SDS. Lysates were centrifuged at 14.0006g at 4uC and
precleared with 50 ml of G-sepharose beads (GE Healthcare) and
subsequently incubated with antibodies of interest for 12–24 hours at
4uC. Protein G-sepharose beads (50 ml) were then added for 4 hours
at 4uC to capture the immune complexes. Beads were washed 4 times
with co-IP buffer and 1 time with high stringency co-IP buffer (with
300 mM NaCl). For all experiments, two negative controls consisted
of a sample lacking the primary antibody (Beads) and a sample
incubated with IgG. Resulting immune-bound complexes were eluted
in Laemmli buffer and analysed by SDS-PAGE andWestern blotting.
PtdIns3P ELISA
PtdIns3P mass ELISA was performed on lipid extracts from
whole zebrafish embryos from 3 independently injected clutches
(number of embryos in each clutch = 50) following manufacturer’s
recommendations (Echelon Biosciences, Salt Lake City, UT,
USA). Extracted lipids were resuspended in PBS-T with 3%
protein stabilizer and then spotted on PtdIns3P Mass ELISA plate.
Following ELISA, PtdIns3P levels were detected by measuring
absorbance at 450 nm on a plate reader. Specific amounts were
determined by comparison of values to a standard curve generated
with simultaneous readings of known amounts of PtdIns3P.
RT-PCR
To detect mtmr12 knockdown in 3 dpf zebrafish embryos, RNA
was prepared using RNeasy fibrous tissue mini kits (Qiagen,
Valencia, CA, USA). cDNA was prepared using high capacity
RNA-to-cDNA mastermix kits (Ambion, Austin, TX, USA). RT-
PCR was performed using equal amounts of RNA from control
and mtmr12 morphant zebrafish. To measure Mtmr12 and Mtm1
expression levels in C2C12 cells, total RNA was purified from
C2C12 (from 0 to 9 days of differentiation) cells using Trizol
reagent (Invitrogen) according to manufacturer’s instructions.
cDNAs were synthesized from 2 to 5 mg of total RNA using
Superscript II reverse transcriptase (Invitrogen) and random
hexamers. Quantitative PCR amplification of cDNAs was
performed on Light-Cycler 480 and Light-Cycler 24 instruments
(Roche Applied Sciences) using 58uC as melting temperature.
Gapdh gene expression was used as control as expression of this
gene varies little during C2C12 cell differentiation. Primers used
were: Mtm1 (F: catgcgtcacttggaactgtgg, R : gcaattcctcgagcctcttt),
Mtmr12 (F: tgtctgaggtacacaaaggag, R: agccttcattcacactcactg) and
Gapdh (F: agctttccagaggggccatccaca, R : ccagtatgactccactcacggcaa).
Electron microscopy
Zebrafish embryos were fixed in formaldehyde-glutaraldehyde-
picric acid in cacodylate buffer overnight at 4uC followed by
osmication and uranyl acetate staining. Subsequently, embryos
were dehydrated in a series of ethanol washes and finally
embedded in TAAB epon (Marivac Ltd., Nova Scotia, Canada).
95 nm sections were cut with a Leica Ultracut microtome, picked
up on 100 m Formvar coated Cu grids and stained with 0.2%
Lead Citrate. Sections were viewed and imaged under a Philips
Tecnai BioTwin Spirit Electron Microscope (Electron Microscopy
Core, Harvard Medical School).
Quantification and statistical analysis
Centrally nucleated myofibers were quantified by analyzing
serial sections from 6 different embryos. The relative number of
centrally nucleated fibers in the middle somites (10–13) were
counted. Total number of triads were counted in at least 15
myofibers within each embryo (n= 5 embryos). Body length was
measured in 10–15 embryos in each group. Data were statistically
analyzed by parametric Student t-test (two tailed) and were
considered significant when P,0.05. All data analyses were
performed using XLSTAT software.
Supporting Information
Movie S1 Touch evoke response assay in wild-type (fish1),
mtmr12 (fish2), mtm1 (fish3) and mtm1-mtmr12 (fish4) morphant
embryos at 3 dpf.
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